Sai Life Sciences Opens New, State-of-the-Art Research & Technology Centre in Hyderabad

Sai Life Sciences

AsiaNet  85142

 

HYDERABAD, India, August 15, 2020 /PRNewswire=KYODO JBN/ --

 

- Completes first phase in committed investment of US$ 150M (> INR 1000 Cr)

 

- Sri KT Rama Rao, Hon’ble Minister for Industry & Commerce and IT, Government

  of Telangana inaugurates the facility

 

Sai Life Sciences, one of India’s fastest growing Contract Development &

Manufacturing Organizations (CDMOs), [

https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=resandtechcentre]

today announced the inauguration of its new Research and Technology (R&T)

Centre in Hyderabad, India. Sri K T Rama Rao, Hon’ble Minister for Industry &

Commerce and IT, Government of Telangana formally inaugurated the facility in

the presence of other dignitaries.

 

Speaking on the occasion, Sri KT Rama Rao said, “I’m very happy that the

esteemed leadership of Sai Life sciences has considered Telangana for setting

up their new R&D centre. Life Sciences is one of the key focus sectors for the

Government of Telangana. Hyderabad serves more than 1000 global innovators in

their vision to develop innovative and affordable medicines for the world. I

sincerely congratulate the entire team of Sai Life Sciences, not only for the

new Research & Technology Centre but, also for their work towards the

development and manufacturing of new life saving medicines.”

 

Built with an aspiration to achieve the best global benchmarks in lab

infrastructure, the new R&T facility [

https://www.sailife.com/research-technology-centre-hyderabad/?utm_source=pr&utm_medium=web&utm_campaign=resandtechcentre]

has several unique aspects such as intelligent & ergonomic lab design to

enhance safety and productivity, advanced automation for seamless data capture

during process development, lean & 5S approach to enhance productivity and

collaborative workspaces for engendering innovation.

 

Making the announcement, Krishna Kanumuri, CEO & Managing Director of Sai Life

Sciences said, “Our philosophy behind building this new facility was to go

beyond what the norm is in India and to create what our global innovator

partners expect in their inhouse capabilities.” He further added, “We are an

example of what is possible in Hyderabad’s rich life sciences ecosystem. Today,

as we build world class R&D capabilities and invest in nurturing talent with

deep domain expertise, I can unhesitatingly say, Hyderabad is truly a city

where pharma dreams are made.”

 

The new 83,000 sq.ft. (7700 sq.m.) facility houses state-of-the-art research

capabilities and advanced technology platforms, augmenting the company’s

capabilities in providing superior scientific solutions to its pharma and

biotech innovator customers globally. It has 24 chemistry labs with 250 fume

hoods, analytical labs, fully equipped technology suite and a dedicated process

safety lab.

 

Sai Life Sciences began a process of organizational transformation in 2019

reinventing itself as a new generation global CDMO. Through this initiative,

named Sai Nxt, the company is investing over US$ 150M (> INR 1000 Cr) to expand

and upgrade its R&D and manufacturing facilities, induct top-notch global

scientific and leadership talent, strengthen automation and data systems, and

above all raise the bar for safety, quality and customer focus.

 

About Sai Life Sciences

 

Sai Life Sciences is a full-service CDMO driven by a vision to support the

launch of 25 new medicines by 2025.  It works with innovator pharma and biotech

companies globally, accelerating the discovery, development and manufacture of

complex small molecules. A pure-play CDMO, Sai Life Sciences has served a

diverse set of NCE development programs, consistently delivering value based on

its quality and responsiveness. Today, it works with 7 of the top 10 large

pharma companies, as well as several small and mid-sized pharma & biotech

companies. Sai Life Sciences is privately held and backed by global investors,

TPG Capital and HBM Healthcare Investments. https://www.sailife.com/

 

Photo - https://mma.prnewswire.com/media/1228693/Sai_Life_Sciences.jpg

Photo - https://mma.prnewswire.com/media/1228696/Sci_Life_Sciences_Centre.jpg

Logo - https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg

 

Source : Sai Life Sciences

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中